Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells
- 304 Downloads
The extracellular region (EC) of the vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2) contains seven immunoglobulin-like (Ig-like) domains that are required for specific ligand binding and receptor dimerization. Studies of domain 4–7 deletions and substitutions provided insights into the interaction between receptors in the absence of VEGF. In this study, we investigated the effect of domain 4 in ligand-independent VEGFR-2 dimerization and activation in human vascular endothelial cells and human breast cancer cells.
To confirm the role of domain 4 in ligand-independent receptor dimerization and activation, two VEGFR-2 fragments with and without domain 4, KFP1 and KFP2, were generated by recombinant DNA technology. We measured the affinity of KFP1 and KFP2 with VEGFR-2, and the roles of KFP1 and FKP2 in dimerization and phosphorylation of VEGFR-2. We also evaluated the effect of KFP1 and FKP2 on cell proliferation and migration in HUVECs and in human breast cancer cells.
We showed that KFP1 did not affect the interaction of VEGFR-2 and VEGF but bound VEGFR-2 in the absence of VEGF. Furthermore, cross-linking and cross-linking immunoblotting demonstrated that KFP1 could form a complex with VEGFR-2, which resulted in VEGFR-2 dimerization in the absence of VEGF. Importantly, we found that the KDR fragment with domain 4 induced phosphorylation of VEGFR-2, as well as phosphorylation of downstream receptor kinases in HUVECs and VEGFR-2-positive breast cancer cells. Consistent with these results, this ligand-independent activation of VEGFR-2 also promoted downstream signaling and cell proliferation and migration.
The domain 4 of VEGFR-2 plays an important role in the interaction between VEGFR receptors in the absence of VEGF.
KeywordsVEGFR-2 Domain 4 Dimerization Activation HUVECs Breast cancer cells
Vascular endothelial growth factor
Vascular endothelial growth factor receptor-2
Kinase insert domain receptor
Receptor tyrosine kinase
Extracellular signal-regulated kinase
Platelet-derived growth factor receptor
Epidermal growth factor receptor
Fibroblast growth factor receptor
Stem cell factor receptor
Endothelial cell medium
Enzyme-linked immunosorbent assay
Compliance with ethical standards
Conflict of Interest
All authors declare no actual, potential, or perceived conflict of interest that would prejudice the impartiality of the article.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR (2010) Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophy Acta 1806(1):108–121Google Scholar
- 8.Ryden L, Jirstrom K, Halund M, Stal O, Ferno M (2010) Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 120(2):491–498CrossRefPubMedGoogle Scholar
- 12.Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M (1998) Mapping of the site involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 273(47):31283–31288CrossRefPubMedGoogle Scholar
- 17.Kisko K, Brozzo MS, Missimer J, Schleier T, Menzel A, Leppanen VM, Alitalo K, Walzthoeni T, Aebersold R, Ballmer-Hofer K (2011) Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering. FASEB J 25(9):2980–2986CrossRefPubMedGoogle Scholar
- 27.Tao Q, Backer MV, Backer JM, Terman BI (2001) Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4–7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling. J Biol Chem 276(24):21916–21923CrossRefPubMedGoogle Scholar
- 29.Hyde CA, Giese A, Stuttfeld E, Abram Saliba J, Villemagne D, Schleier T, Bina HK, Ballmer-Hofer K (2012) Targeting extracellular domain D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor sites. Mol Cell Biol 32(19):3802–3813CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Svensson S, Jirstrom K, Ryden L, Roos G, Emdin S, Ostrowski MC, Landberg G (2005) ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24(27):4370–4379CrossRefPubMedGoogle Scholar
- 41.Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, Lynch MP, Rueda BR (2006) Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 281(36):26320–26328CrossRefPubMedGoogle Scholar
- 44.Gockel I, Moehler M, Frerichs K, Drescher D, Trinh TT, Duenschede F, Borschitz T, Schimanski K, Biesterfeld S, Herzer K, Galle PR, Lang H, Junginger T, Schimanski CC (2008) Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol Rep 20(4):845–850PubMedGoogle Scholar
- 47.Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG (2008) High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39(12):1835–1843CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Su L, Ren X, Wei H, Zhao L, Zhang X, Liu J, Su C, Tan L, Li X (2016) Intravitreal Conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy. Rentina 36(5):938–943Google Scholar